CARLHIGH SIGNALFINANCIAL10-Q

CARL completed a successful IPO in July 2025, dramatically improving its balance sheet with cash increasing 245% to $115.4M and eliminating its equity deficit, while operating losses widened significantly as R&D spending accelerated.

The IPO fundamentally transformed CARL's financial position, providing substantial runway for growth investments and eliminating near-term liquidity concerns. However, the 74% increase in operating losses and 56% deterioration in operating cash flow indicates the company is aggressively investing in growth, which investors should monitor for execution risk and cash burn trajectory.

Comparing 2025-11-06 vs 2025-08-28View on EDGAR →
FINANCIAL ANALYSIS

CARL's financial profile was dramatically transformed by its July 2025 IPO, with cash surging 245% to $115.4M and stockholders' equity swinging from a deficit of $83.1M to positive $106.7M, providing substantial financial flexibility. However, operating performance deteriorated significantly with losses widening 74% and operating cash flow declining 56% as the company ramped R&D spending by 61%, though this was partially offset by 60% gross profit growth. The overall picture shows a well-capitalized company aggressively investing for growth but burning cash at an accelerated rate, requiring careful monitoring of execution and cash utilization efficiency.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+244.7%
$33.5M$115.4M

Cash position surged 244.7% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+228.4%
-$83.1M$106.7M

Equity base grew 228.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+184.6%
$46.2M$131.5M

Current assets grew 184.6% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+153.2%
$53.3M$134.9M

Asset base grew 153.2% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
-73.9%
-$12.2M-$21.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-68.2%
-$12.5M-$21.0M

Net income declined 68.2% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+60.8%
$7.3M$11.8M

R&D investment increased 60.8% — signals commitment to future product development, though near-term margin impact.

Gross Profit
P&L
+60.1%
$16.5M$26.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Cash Flow
Cash Flow
-55.7%
-$15.2M-$23.7M

Operating cash flow fell 55.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+52.8%
$720K$1.1M

Interest expense surged 52.8% — significant debt increase or rising rates materially impacting earnings.

LANGUAGE CHANGES
NEW — 2025-11-06
PRIOR — 2025-08-28
ADDED
Financial Statements (Unaudited) 1 Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2025 and 2024 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Notes to Condensed Financial Statements 7 Item 2.
Food and Drug Administration ( FDA ) cleared the aprevo interbody implants through its 510(k) regulatory pathway for the correction of adult lumbar spinal deformity in December 2020 and several degenerative conditions of the lumbar spine in August 2022.
The Company commenced its limited clinical release with its first U.S.
patient implant in February 2021, and in October 2021, the Company commenced its U.S.
Immediately prior to the closing of the IPO on July 24, 2025, all shares of the Company s convertible preferred stock converted into shares of the Company s common stock.
+7 more — sign up free →
REMOVED
Financial Statements (Unaudited) 1 Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2025 and 2024 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit for the Three and Six Months Ended June 30, 2025 and 2024 3 Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 4 Notes to Condensed Financial Statements 6 Item 2.
Food and Drug Administration ( FDA ) cleared the aprevo interbody implants for the correction of adult lumbar spinal deformity through its 510(k) regulatory clearance pathway in December 2020.
After FDA clearance, the Company commenced its limited clinical release, with its first U.S.
Initial Public Offering Immediately prior to the closing of the Company s initial public offering on July 24, 2025, all shares of the Company s convertible preferred stock converted into shares of the Company s common stock.
The shares and proceeds from the IPO are not reflected in the condensed financial statements as of and for the three and six months ended June 30, 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →